Häufig gestellte Fragen

What is Brexucabtagene Autoleucel used for?

A CAR-T cell therapy in which a patient's own T cells are genetically modified to express chimeric antigen receptors targeting CD19 on cancer cells. It is used to treat relapsed or refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia. Like other CAR-T therapies, it carries risks of cytokine release syndrome and neurological toxicity.

Is Brexucabtagene Autoleucel an approved drug?

Yes, Brexucabtagene Autoleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

• ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594618. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.